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on the waiting list, while improvement on the MI (d = 0.50) 
was nearly significant. Secondary outcomes were consistent 
with ACT theory. Follow-up assessments indicated a stable 
and continued improvement after treatment. The dropout 
rate was low (9%).  Conclusions: Despite a clinically challeng-
ing sample and brief treatment administered by novice ther-
apists, patients who received ACT reported significantly 
greater changes in functioning and symptomatology than 
those on the waiting list, with medium-to-large effect sizes 
that were maintained for at least 6 months. These proof-of-
principle data suggest that ACT is a viable treatment option 
for treatment-resistant PD/A patients. Further work on switch-
ing to psychotherapy for nonresponders is clearly needed. 
 © 2015 S. Karger AG, Basel 
 Introduction 
 Nonresponsiveness to treatment is generally acknowl-
edged as a considerable problem, with estimates ranging 
from 25 to 50% of patients who complete state-of-the-art 
treatments. Even in the case of anxiety disorders, which 
are generally considered to respond favorably to cogni-
tive-behavioral treatment (CBT)  [1] , more than 20% of 
patients do not reach the criteria for high end-state func-
tioning. These estimates do not include patients that drop 
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 Abstract 
 Background: Nonresponsiveness to therapy is generally ac-
knowledged, but only a few studies have tested switching to 
psychotherapy. This study is one of the first to examine the 
malleability of treatment-resistant patients using acceptance 
and commitment therapy (ACT).  Methods: This was a ran-
domized controlled trial that included 43 patients diagnosed 
with primary panic disorder and/or agoraphobia (PD/A) with 
prior unsuccessful state-of-the-art treatment (mean number 
of previous sessions = 42.2). Patients were treated with an 
ACT manual administered by novice therapists and followed 
up for 6 months. They were randomized to immediate treat-
ment (n = 33) or a 4-week waiting list (n = 10) with delayed 
treatment (n = 8). Treatment consisted of eight sessions, im-
plemented twice weekly over 4 weeks. Primary outcomes 
were measured with the Panic and Agoraphobia Scale (PAS), 
the Clinical Global Impression (CGI), and the Mobility Inven-
tory (MI).  Results: At post-treatment, patients who received 
ACT reported significantly more improvements on the PAS 
and CGI (d = 0.72 and 0.89, respectively) than those who were 
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out or remain impaired despite some measurable im-
provement  [2] . 
 Empirical studies on treatment-resistant patients are 
rare  [3, 4] , and empirically based guidelines to advise cli-
nicians on how to help treatment nonresponders are lack-
ing. Very few randomized controlled trials have exam-
ined the effects of switching from a psychotherapy that 
failed to adequately work to a different psychotherapy. 
Instead, most treatment-refractory studies are pharma-
cological in nature, both in terms of the original treat-
ment and the alternative response  [5] . Even when psy-
chological treatments are examined, they are usually ad-
ministered either directly following or in combination 
with pharmacology  [6] . The problem of nonresponse is 
particularly challenging when state-of-the-art psycholog-
ical interventions fail, such as CBT for patients with pan-
ic disorder and agoraphobia. Evidence exists that contin-
ued exposure can help in some cases  [7] . A recent study 
 [8] also addressed this issue in a multisite randomized 
controlled clinical trial of patients with primary panic dis-
order and/or agoraphobia (PD/A). These authors exam-
ined whether the addition of 9 monthly maintenance 
(‘booster’) sessions would increase the likelihood of sus-
tained improvement and reduced relapse. Indeed, be-
yond maintenance of improvements, they also observed 
symptom reduction in previous nonresponders.
 The systematic examination of treatment in nonre-
sponders and the treatment development in general have 
been impeded by the disproportionate concentration on 
comparing the efficacy of various treatments  [9] . Trials 
on groups of patients with specific characteristics, such as 
failed treatment  [10] and close examinations of processes, 
are needed. Examining the mechanisms of action of treat-
ment has only recently become the focus of randomized 
controlled trials (RCTs)  [11–13] . Outside of this focus on 
positive effects remains the important challenge of what 
to do for the sizeable minority who do not respond to 
treatment, which is a pressing demand that has been ac-
knowledged in efforts to formulate clinical approaches to 
sequential treatment  [2, 10, 14, 15] .
 Acceptance and commitment therapy (ACT) is a cog-
nitive-behavioral therapy that teaches psychological 
concepts, such as mindfulness, acceptance, cognitive de-
fusion (flexible distancing from the literal meaning of 
cognitions), and other strategies to increase psychologi-
cal flexibility and promote behavior change consistent 
with personal values. Within ACT, psychological flexi-
bility is defined as the capacity to make contact with ex-
perience in the present moment, and – based on what is 
possible in that moment – to persist in or change behav-
ior in the pursuit of goals and values  [16, 26] . Clinical 
studies and RCTs provide evidence that ACT is effective 
for a wide array of disorders  [17] , including primary 
treatment for anxiety disorders, such as social anxiety 
disorder  [18] , panic disorder  [19] , and mixed anxiety dis-
orders  [20] . 
 A unique aspect of ACT is its focus on helping pa-
tients learn to interact more flexibly with their symp-
toms (e.g., simply observe them as opposed to trying to 
eliminate them) and to continue pursuing their values 
and life goals even in the presence of symptoms  [16] . 
ACT is therefore especially suitable to help treatment-
resistant patients, precisely because the possibility that 
symptoms may persist has been elegantly integrated into 
its treatment rationale. Accordingly, this therapy helps 
patients abandon their longstanding, unsuccessful strug-
gle with their symptoms. This stance allows for the pos-
sibility of meaningfully improving patients’ lives, even 
when symptoms persist, and suggests that ACT could be 
a particularly efficacious and viable treatment option for 
patients who did not respond to state-of-the-art treat-
ments.
 In this study, we aimed to test the efficacy of an ACT 
intervention for patients with treatment-resistant pri-
mary PD/A. We hypothesized that (1) the ACT treat-
ment group would report a significantly greater reduc-
tion in symptoms and an increase in functioning com-
pared to the patients on the waiting list (WL; hypothe-
sis 1), (2) treatment gains would be stronger in ACT-
specific processes (i.e., acceptance, defusion, mindful-
ness) than in panic disorder-specific processes or more 
general symptom measures (hypothesis 2); and (3) treat-
ment gains would be maintained over 6 months (hy-
pothesis 3). 
 Methods 
 Please see the online supplementary material (for all online 
suppl. material, see www.karger.com/doi/10.1159/000370162) for 
details on Methods and Results.
 Inclusion Criteria 
 Inclusion criteria were a reliable diagnosis of PD/A, age be-
tween 18 and 65 years, a Mobility Inventory (MI) score  ≥ 1.5  [21] , 
a Clinical Global Impression (CGI) scale score  ≥ 4 (‘moderately ill’) 
 [22] , and informed consent. Additionally, all patients were re-
quired to have had one or more previous courses of psychological 
and/or pharmacological treatment consistent with state-of-the-art 
practice. For psychotherapy, this was defined as  ≥ 20 sessions of 
empirically supported treatments in which all patients had re-
ceived interventions inherent to these treatments, such as expo-
sure in situ, interoceptive exposure, cognitive restructuring, etc.
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(n = 38, 88.4%). For pharmacology, this was defined as intake of 
an approved drug at least at the minimum dosage and length as 
recommended by national and international therapy guidelines 
 [23, 24] (n = 14, 32.6%). 
 Exclusion Criteria 
 Exclusion criteria were inadequate previous treatment, concur-
rent psychotherapy, and diagnoses of alcohol dependence, bipolar 
disorder, psychotic or eating disorders, benzodiazepine or other 
drug dependence. Patients who were actively suicidal were also 
excluded. If patients were taking psychopharmacological agents, 
they had to agree not to change the dose during the trial. 
 Design 
 This was a randomized, WL-controlled clinical trial conducted 
in Germany between June 2010 and June 2012, with the final fol-
low-up assessment in December 2012. Patients and assessors were 
blinded to the hypotheses. Patients were randomized to either im-
mediate treatment (n = 33) or a 4-week WL (n = 10). For ethical 
reasons, patients from the WL were offered treatment immedi-
ately after the 4-week waiting period (delayed treatment; n = 8). 
Patients did not receive any treatment during the follow-up peri-
od, and a total of 51 cases were included in the analysis ( fig. 1 ).
 Randomization 
 An independent statistician randomly allocated patients to im-
mediate treatment or WL with a 3: 1 ratio .
 Intervention 
 A manual of ACT for anxiety disorders  [25] was adapted for this 
trial. This manual was already successfully employed in a large ran-
domized clinical trial comparing ACT and CBT  [20] . The brief treat-
ment consisted of eight sessions administered twice weekly over 4 
weeks. The sessions lasted between 90 and 120 min. ACT is a behav-
ioral treatment with the aim of promoting psychological flexibility 
and consists of six processes: acceptance, present moment aware-
ness, defusion, self-as-context (observer perspective), value clarifica-
tion, and committed action. Patients worked towards becoming 
more aware and accepting of anxiety and other uncomfortable emo-
tions and experiences. This stance was adopted so that they could 
more willingly engage in important aspects of their life, irrespective 
of the presence of uncomfortable emotions and thoughts  [27] . 
 Therapists 
 Therapists were graduate students of a CBT university training 
center who were well trained and had experience in CBT but had 
no prior experience treating patients with ACT. Therapists were 
WL (control) group (n = 10)ACT group (n = 33)
Included and randomized (n = 43)
Screened (n = 290)
Informed consent (n = 59)
Assessed for eligibility (n = 57)
Delayed ACT group (n = 8)
Received post (n = 10) 
Analyzed (n = 10)
• Still met inclusion criteria (n = 8)
• Still met inclusion criteria, but not 
 interested (n = 1)
• No longer met inclusion criteria (n = 1)
Received post (n = 28) Received post (n = 8)
Received FU (n = 27*)
Not available for FU (n = 2)
Analyzed (n = 33)
Received FU (n = 7)
Not available for FU (n = 1)
Analyzed (n = 8)
Lost to post (n = 5)
Reason:
• Interrupted contact (n = 5)
Not assessed for eligibility (n = 2)
Reasons:
• Did not meet inclusion criteria (n = 1)
• Not interested (n = 1)
Excluded (n = 14)
Reasons:
• Did not meet inclusion criteria (n = 9)
• Not interested (n = 4)
• Other reasons (n = 1)
*Includes 1 proxy from a dropout after session 3 Fig. 1. Flowchart of patients included in the 
study. 
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trained via a 3-day intensive training, readings, self-study, and 
were required to pass a competency test. 
 Treatment Integrity 
 All treatment sessions were videotaped, and 19.7% (60/305) of 
all conducted sessions were analyzed for treatment adherence and 
therapist competency. The ratings were made by one of the man-
ual developers (G.E.) who was not involved in the study manage-
ment or clinical supervision. Ratings were made using the Drexel 
University ACT/CT Therapist Adherence and Competence Rating 
Scale  [28] . On a scale from 1 (poor) to 5 (excellent), therapists 
demonstrated very good levels on items measuring (a) knowledge 
(mean ± SD, 3.9 ± 1.1), (b) skill (3.7 ± 1.4), (c) overall adherence 
to the manual (4.0 ± 1.3), and (4) overall performance (3.9 ± 1.4). 
Additionally, therapists were judged to have very good relation-
ships with the patients (4.1 ± 0.9).
 Assessors 
 Assessors were blinded to the treatment conditions. Before the 
study, assessors completed a 3-day training, testing, and subse-
quent certification of the assessment procedures. Regular supervi-
sion was conducted to maintain consistent strategies across asses-
sors and questions.
 Assessment 
 Patients completed measurements at baseline, post-treatment, 
and after 6 months of follow-up (FU-6). The primary outcome 
measures included overall panic and agoraphobia symptomatology 
(Panic Agoraphobia Scale, PAS  [29, 30] ), global clinical impression 
and functioning (CGI  [31] ), and agoraphobic avoidance (MI  [32] ). 
 Diagnoses were derived by the CIDI and validated by expert 
clinicians  [33–38] . Additional measures targeting three areas were 
included: (1) panic-specific processes, (2) general symptomatology, 
and (3) ACT-specific processes. First, panic-specific processes were 
included that have been found to mediate other forms of CBT for 
PD/A and that are commonly used in the assessment and treatment 
of PD/A. These included: fear related to bodily sensations (Bodily 
Sensations Questionnaire, BSQ  [39] ), the Agoraphobic Cognitions 
Questionnaire (ACQ  [39] ), and the Anxiety Sensitivity Index (ASI 
 [40] ). Second, standard measures of more general anxiety and de-
pression were assessed, including the Hamilton Anxiety Rating 
Scale (SIGH-A  [22] ), the Beck Depression Inventory (BDI-II  [41] ), 
and the Beck Anxiety Inventory (BAI  [42] ). Finally, measures for 
specific processes assumed to be active in ACT were difficulty with 
emotional regulation (Difficulty with Emotion Regulation Scale, 
DERS  [43] ), acceptance/thought suppression (White Bear Sup-
pression Inventory, WBSI  [44] ), mindfulness (Kentucky Inventory 
of Mindfulness Skills, KIMS  [45] ), and defusion (Believability in 
Anxious Feelings and Thoughts Questionnaire, BAFT  [46] ) . 
 Statistical Analysis  
 Hypothesis 1 (Efficacy) 
 For all primary and secondary outcomes, hypothesis 1 was test-
ed using ANCOVA with baseline outcome values as covariates. 
For each comparison, the ACT treatment group was compared to 
the WL in terms of post-treatment. Analyses were run both for 
treatment completers and intent to treat following multiple impu-
tations  [47] . Only results based on completers are reported here 
because all outcomes were comparable (online suppl. material). 
Preliminary analyses found no differences in any of the outcome 
analyses between patients who received immediate treatment and 
those who first went through the WL, nor were there differences 
between patients with and those without previous pharmacologi-
cal treatment. 
 Hypothesis 2 (Differential Response across Disorder-Specific 
Processes, General Symptoms, and ACT-Specific Processes) 
 We set up a multivariate random intercept model of the com-
bined secondary outcomes to test whether treatment gains would 
be stronger in ACT-specific processes (i.e., DERS, WBSI, KIMS, 
and BAFT) than in panic disorder-specific process measures (i.e., 
BSQ, ACQ, and ASI) or in more general symptom measures (i.e., 
SIGH-A, BDI-II, and BAI). 
 Hypothesis 3 (Treatment Gain and Maintenance) 
 To test hypotheses 2 and 3, we used a linear mixed model  [48] 
with a random intercept, assuming equal covariances among the 
three time points. 
 Response Rate 
 Consistent with previous research, response was defined as
≤18 (‘mild’ or less) on the PAS and ‘mild’ or less on the CGI  [11, 
12, 29, 30] .
 Results 
 Sample Characteristics and Randomization Check 
 The participants were 43 patients diagnosed with pri-
mary PD/A. They were largely female (69.8%), with an 
average age of 36.9 years. In addition to PD/A, patients 
endorsed 2.0 comorbid disorders on average. The average 
number of previous therapies was substantial: mean = 
42.3, median = 25.0 psychotherapy sessions 1 and 2.1 val-
id psychopharmacological agents ( table 1 ). No significant 
differences were observed between the ACT and the WL 
group at baseline on any outcome measure.
 Attrition 
 Among the 51 cases, 46 (90.2%) completed post-as-
sessment. Among the 41 patients who began treatment, 
37 (90.2%) completed all eight sessions ( fig.  1 ) and 1 
(2.4%) dropped out after baseline, but prior to the first 
session. Three patients (7.3%) received a partial dose of 
therapy. Attrition was unrelated with any particular ele-
ment of the treatment, as the dropouts during treatment 
occurred once following sessions 1, 3, and 5. One patient 
attended all eight sessions, but did not complete post-as-
sessment.
 1    Regulations in Germany guarantee patients 25 sessions of short-term em-
pirically supported CBT. Charted psychotherapists administered the thera-
pies with quality controls administered by the regulated German social in-
surance system.  
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 Adverse Events 
 The patients did not report any adverse events during 
the treatment or during the FU-6 period. 
 Treatment Efficacy (ACT vs. WL: Hypothesis 1) 
 Comparisons between the ACT and the WL group 
were made only at post-treatment due to the study design.
 Primary Outcomes 
 As expected, the ACT group improved significantly 
more than the WL group in terms of panic/agoraphobic 
symptoms (PAS: d = 0.72) and general functioning (CGI: 
d = 0.89) ( table 2 ). Despite a medium effect size, the com-
parison ACT/WL was nonsignificant on the MI (d = 
0.50). Results based on multiple imputation resulted in 
comparable values (see online suppl. material). 
 Secondary Outcomes 
 The secondary outcome measures targeted three areas: 
PD/A-specific factors, general symptoms, and ACT-spe-
cific process measures. With the exception of two PD/A-
specific measures (ACQ and ASI), the ACT group per-
formed significantly better than the WL group on all sec-
ondary measures ( fig. 2 ). Whereas the difference between 
the ACT and the WL group resulted in small-to-medium 
effects for the panic-specific factors of ACQ and ASI, 
comparisons between the groups resulted in medium-to-
large effects for general symptoms, and large-to-very 
large effects for ACT-specific process measures. 
 Differential Response across Processes and Symptoms 
(Hypothesis 2) 
 The interaction between treatment group and differ-
ential category was highly significant (likelihood ratio = 
14.6, p < 0.001). Thus treatment group results were high-
est for the category ACT-specific (–1.08, SE = 0.23), fol-
lowed by panic-specific (–0.61, SE = 0.22), and general 
symptoms (–0.45, SE = 0.22). Differences for these effects 
 Table 1. Baseline characteristics by treatment condition
ACT (n = 33)  WL (n = 10)
Age, years 36.7 ± 8.9 37.5 ± 8.9
Previous sessions 42.6 ± 42.4 41.2 ± 33.4
Comorbid diagnoses 1.9 ± 3.2 2.3 ± 2.7
Sex, n (%)
Male 11 (33.3) 2 (20.0)
Female 22 (66.7) 8 (80.0)
Years of education
8 1 ± 3.0 1 ± 10.0
10 14 ± 42.4 4 ± 40.0
12 – 13+ 13 ± 39.4 2 ± 20.0
No formal degree 5 ± 15.2 3 ± 30.0
Living arrangement
With parents 0 0
Alone 7 ± 21.2 0
With partner 20 ± 60.6 6 ± 60.0
Other 6 ± 18.2 4 ± 40.0
Employment
University student 1 ± 3.0 0
Job training 1 ± 3.0 1 ± 10.0
Employed 20 ± 60.6 6 ± 60.0
Unemployed 6 ± 18.2 0
Other 5 ± 15.2 3 ± 30.0
Social class
Lowest 1 ± 3.0 0
Lower middle 7 ± 21.2 2 ± 20.0
Middle 19 ± 57.6 4 ± 40.0
Upper middle 1 ± 3.0 1 ± 10.0
Upper 0 0
Marital status
Married 6 ± 18.2 4 ± 40.0
Divorced/widowed/separated 5 ± 15.2 0
Never been married 17 ± 51.5 3 ± 30.0
Comorbidity, 12-month diagnoses
Alcohol abuse 1 ± 3.0 0
Alcohol dependence 0 0
Generalized anxiety disorder 5 ± 15.2 0
Social phobia 12 ± 36.4 3 ± 30.0
Any specific phobia 12 ± 36.4 3 ± 30.0
Obsessive-compulsive disorder 6 ± 18.2 3 ± 30.0
Posttraumatic stress disorder 1 ± 3.0 1 ± 10.0
Major depressive episodes 8 ± 24.2 4 ± 40.0
Dysthymia 5 ± 15.2 2 ± 20.0
Pain disorder 7 ± 21.2 2 ± 20.0
Comorbid diagnoses, number
None 8 ± 24.2 0
1 – 2 15 ± 45.4 5 ± 50.0
3 – 4 6 ± 18.2 4 ± 40.0
5+ 4 ± 12.1 1 ± 10.0
Numbers vary across categories due to missing values. 
 Table 2.  Primary outcome variables between group effects at post-
treatment
Difference between ACT 
and WL at post-treatment
Difference between group 
 effects at post-treatment
Mean SE F p d
PAS –6.8 3.0 4.99 0.02 0.72
CGI –1.0 0.3 8.20 0.00 0.89
MI –0.3 0.2 2.18 0.07 0.50
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were significant for ACT-specific versus panic-specific 
and ACT-specific versus general symptoms, but not for 
panic-specific versus general symptoms.
 Within-Group Change and Maintenance of Gains 
following Treatment (Hypothesis 3).  
 Across all primary and secondary variables, values at 
FU-6 were statistically improved compared to baseline. 
They continued to significantly improve between post-
treatment and FU-6 (p < 0.05) for panic symptoms and 
were nearly significant for MI (p = 0.06) and CGI (p = 
0.06) ( fig. 3 ). No variable demonstrated statistically sig-
nificant worsening between post-treatment and FU-6. 
Taken together, these results clearly suggest that treat-
ment gains are maintained for at least 6 months, do not 
recede, and to some degree continue to improve during 
this generalization period. 
 Response Rates 
 Categorical response rates were calculated at both 
post-treatment and FU-6. At post-treatment, response 
rates for PD/A symptomatology (PAS) and functioning 
(CGI) were 70 and 57%, respectively. At FU-6, response 
rates for PD/A symptomatology and functioning were 80 
and 52% respectively. 
 Generalization (Change in Diagnoses) 
 The number of diagnoses was again calculated at FU-6 
in order to test the breadth of the treatment effect. The 
mean number of diagnoses at FU-6 (1.2) was significant-
ly reduced from that at baseline (1.8;  t 40 = 2.72, p < 0.01).
 Discussion 
 This RCT demonstrated the efficacy of switching to a 
psychological treatment (ACT) for treatment-resistant 
patients with PD/A. Medium-to-large effects were ob-
served on primary indices of PD/A symptoms and gen-
eral functioning. These effects were significantly superior 
to those of the WL patients. Effects for agoraphobic 
avoidance were nearly statistically significant in compar-
ison to the WL, with a medium-controlled effect size. 
These improvements were either maintained or improved 
in the 6 months following treatment. These results are 
promising and suggest a new option for the sizeable mi-
nority of treatment-resistant patients  [49–51] .
 In the present study, the switch was made to ACT be-
cause this therapy specifically aims to alter the struggle 
with longstanding symptoms by undermining the unnec-
essary struggle with internal psychological barriers in or-
der to engage with what is important in one’s life. To test 
this, we assessed several interrelated clinical processes 
and compared these across numerous measures. Mea-
sures assessing ACT-specific constructs showed the larg-
est effects. In particular, not suppressing uncomfortable 
thoughts and emotions (i.e., acceptance) and not taking 
anxious thoughts and feelings literally (i.e., defusion) 
showed the largest improvement in comparison to the 
WL group. Large effects were also seen on measures of 
mindfulness and general difficulty with unhelpful emo-
tional regulation. Taken as a whole, these results are con-
sistent with one of the central tenets of ACT, namely that 
directly targeting these core processes leads to beneficial 
0 0.2 0.4 0.6 0.8 1.0 1.2 1.4 1.6
Believability in anxious feelings 
 and thoughts (BAFT)
Mindfulness (KIMS)
Supression/acceptance (WBSI)
Emotion regulation difficulty (DERS)
Depression (BDI-II)
Anxiety symptoms (BAI)
General anxiety (HAM-A)
Catastrophic cognitions (ACQ)
Anxiety sensitivity (ASI)
Fear of bodily sensttions (BSQ)
A
CT
pr
oc
es
se
s
PD
/A
pr
oc
es
se
s
G
en
er
al
sy
m
pt
om
s
 Fig. 2. Controlled effect size of secondary 
outcome measures at post-treatment (vs. 
WL group). All effects were significantly 
different (p < 0.05) from the WL group, ex-
cept for the white bars. 
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changes in patients’ lives. These data support this inter-
pretation insofar as the patients reported increases in 
functioning despite some rest symptomatology.
 The pattern across constructs was particularly reveal-
ing. For instance, although anxiety sensitivity (ASI) is one 
of the most consistently identified mediators of treatment 
in PD, the effect in comparison to the WL was small and 
nonsignificant. In contrast, when asked about the believ-
ability of the same type of items (BAFT), the change in 
comparison to the WL resulted in the largest effect size. 
Of clinical importance, this suggests that the content of 
the occurrence of evaluative anxiety statements is not as 
important as whether someone believes the thoughts. 
Consistent with this interpretation, the ACT process 
measures were consistently in the range of large effects, 
whereas traditional panic-related processes and general 
symptomatology were in the small-to-medium range, re-
spectively. Taken as a whole, these results suggest that the 
psychological processes targeted by ACT processes have 
indeed been successfully changed. 
 As observed in this study, treatment gains were clearly 
maintained and continued to improve. Although the im-
provement was not always significant, all tested variables 
showed at least some improvement and none demon-
strated deterioration. Furthermore, the number of co-
morbid diagnoses reduced significantly from baseline to 
follow-up, even though they were not targeted. 
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 Fig. 3. Primary outcome response pattern across baseline, post-treatment, and FU-6. 
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 Results from this study are consistent with studies 
showing that acceptance- and mindfulness-based inter-
ventions achieved better outcomes for patients with co-
morbidity, whereas traditional CBT fared better for pa-
tients with only one disorder  [52] . This is consistent with 
evidence observed in a noncontrolled group of depressed 
patients treated using mindfulness  [53] . As the current 
sample was highly comorbid and treatment-resistant, 
mindfulness- and acceptance-based approaches may be 
especially effective in this population. The present results 
are also consistent with a small study of patients who did 
not adequately respond to exposure therapy, but showed 
improvement after focusing on well-being  [54] . 
 Of clinical importance, the dropout rate in this study 
(9%) was much lower than that in other treatment out-
come studies. For example, two large studies of tradition-
al CBT for panic disorder and agoraphobia reported 
dropout rates ranging between 19.6%  [11] and 28%  [1] , 
with similar rates reported for CBT across anxiety disor-
ders (23%)  [55] and in pharmacological treatments for 
panic disorder (19.8%)  [56] . We have no way of ascertain-
ing the exact reason for the low attrition rate in this study. 
We suspect, however, that switching to the ACT content 
combined with the condensed format of our treatment 
program (i.e., two clearly structured sessions per week 
with regular homework assignments) had a favorable im-
pact.
 This study has several limitations. First, the sample 
size was small and may have led to increased type II error. 
This concern is mitigated by the medium-to-large effect 
sizes observed. Nevertheless, we concentrated our inter-
pretation on effect sizes. Second, we cannot exclude the 
possibility that nonspecific factors were responsible for 
the observed changes as we were unable to include a clin-
ical control group with a different treatment. Although 
the pattern of results, especially the stronger responses in 
ACT-specific measures, mitigates this concern somewhat 
future research will need to address the specificity of these 
findings. Third, including patients into the ACT treat-
ment after they had been on the WL could have poten-
tially led to a systematic bias. As suggested by our pre-
liminary analyses, this did not appear to have an effect on 
the outcomes. Fourth, we were reliant on patients to pro-
vide some details about their treatment history. To assist 
them and to guard against imprecise reporting, we pro-
vided a list of interventions and techniques commonly 
used in empirically supported psychotherapy and other 
techniques and asked them to endorse what they had al-
ready experienced. For patients who had had prior phar-
macotherapy, we compared their medication against na-
tional treatment guidelines. Further, we compared those 
patients for whom we had very detailed information from 
our previous controlled trial  [49] against the others. No 
differences were found for any of these comparisons, sug-
gesting that treatment history was not a confounder and 
that we only treated nonresponders whose previous treat-
ment had been adequate. Fifth, this study only examined 
patients with primary PD/A. Although these patients 
were highly comorbid and the treatment addressed emo-
tions in general, examination of other disorders is needed 
to determine the limits of generalizability. Sixth, we used 
therapists in training who may have a particularly high 
therapy alliance. Finally, although the 6-month assess-
ment results are promising, even longer follow-ups are 
needed to determine if the skills learned during the treat-
ment remain useful during additional challenges that are 
surely to arise in their lives. 
 Notwithstanding these limitations, we conclude that 
switching to psychotherapy can effectively treat treat-
ment-resistant PD/A patients, particularly if the new 
treatment adopts a different approach than the original 
therapy and if it is administered in a structured manner 
that also requires the active involvement of patients  [14, 
15] . We agree that avoidance does indeed matter in treat-
ment-resistant patients  [57] , and ACT appears to be a vi-
able method to address both the numerous manifesta-
tions of subtle and overt experiential avoidance in cases 
that do not otherwise respond to first-line treatments. 
Further tests in other treatment-resistant populations are 
clearly needed and future research should continue to de-
velop and refine interventions for this population.
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